Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9647227rdf:typepubmed:Citationlld:pubmed
pubmed-article:9647227lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0021758lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0214743lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0277784lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:9647227lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:9647227pubmed:issue1lld:pubmed
pubmed-article:9647227pubmed:dateCreated1998-7-9lld:pubmed
pubmed-article:9647227pubmed:abstractTextIL-13, a cytokine similar to IL-4, is a regulator of human B cell and monocyte functions. Biologic effects of IL-13 on primary human NK and T cells have not been well defined. We demonstrate that, in primary NK cells, IL-13, but not IL-4, may induce low levels of IFN-gamma secretion. When NK cells were costimulated with IL-13 and IL-2, IL-13 generally resulted in two types of reactivity: IL-13 synergized with IL-2 to stimulate IFN-gamma production or it modestly inhibited IL-2-mediated IFN-gamma production. In both types of donors, the effect of IL-13 on IL-2-induced IFN-gamma production was in marked contrast to the strong inhibition seen with IL-4 in NK cells. Additionally, IL-13 suppresses IL-2-induced NK cytolytic and proliferative activities although less efficiently than IL-4. In T cells, IL-13 inhibits anti-CD3 mAb/IL-2- or PHA-mediated IFN-gamma production and enhances cytolytic potential. Furthermore, we demonstrate that IL-13, like IL-4, induces distinct STAT6-DNA binding complexes and tyrosine phosphorylation of STAT6 and Janus kinase 3 (JAK3) in NK and T cells. We observed that Abs directed against unique domains of STAT6 have differential effects on complexes in T cells but not in NK cells, suggesting different STAT6 isoforms. These findings show that IL-13 and IL-4 have the ability to regulate NK and T cell activation and that IL-13 is a potent regulator of STAT6 and JAK3 in these cell types.lld:pubmed
pubmed-article:9647227pubmed:languageenglld:pubmed
pubmed-article:9647227pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9647227pubmed:statusMEDLINElld:pubmed
pubmed-article:9647227pubmed:monthJullld:pubmed
pubmed-article:9647227pubmed:issn0022-1767lld:pubmed
pubmed-article:9647227pubmed:authorpubmed-author:YoungH AHAlld:pubmed
pubmed-article:9647227pubmed:authorpubmed-author:OrtaldoJ RJRlld:pubmed
pubmed-article:9647227pubmed:authorpubmed-author:MalabarbaM...lld:pubmed
pubmed-article:9647227pubmed:authorpubmed-author:YuC RCRlld:pubmed
pubmed-article:9647227pubmed:authorpubmed-author:KirkenR ARAlld:pubmed
pubmed-article:9647227pubmed:issnTypePrintlld:pubmed
pubmed-article:9647227pubmed:day1lld:pubmed
pubmed-article:9647227pubmed:volume161lld:pubmed
pubmed-article:9647227pubmed:ownerNLMlld:pubmed
pubmed-article:9647227pubmed:authorsCompleteYlld:pubmed
pubmed-article:9647227pubmed:pagination218-27lld:pubmed
pubmed-article:9647227pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:meshHeadingpubmed-meshheading:9647227-...lld:pubmed
pubmed-article:9647227pubmed:year1998lld:pubmed
pubmed-article:9647227pubmed:articleTitleDifferential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: a comparative study with IL-4.lld:pubmed
pubmed-article:9647227pubmed:affiliationLaboratory of Experimental Immunology, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702, USA.lld:pubmed
pubmed-article:9647227pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9647227pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9647227lld:pubmed